ConductScience.org, home

Paper35339668

Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.

Ye Q and 4 others. Semin Cancer Biol, 2022. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Papers, record 35339668. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35339668

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.
PubMed
Journal
Semin Cancer Biol
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.39
iCite
Revised in PubMed
2022-11-18
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ye QQianling
2Lin YYun
3Li RRuihao
4Wang HHuaiji
5Dong CChunyan

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hematologic NeoplasmsMajor topic
NanoparticlesMajor topic
Humans
Drug Delivery Systems
Immunotherapy

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42269180Mitophagy-mediated immune evasion: Shared strategies of pathogens.Redox Biol2026https://conductscience.org/library/papers/42269180PubMed
41390419HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis.J Nanobiotechnology2025https://conductscience.org/library/papers/41390419PubMed
41127516Inflammation, diabetic foot and related treatments.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41127516PubMed
39679804Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.Adv Sci (Weinh)2025https://conductscience.org/library/papers/39679804PubMed
39043825A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy.Nat Nanotechnol2024https://conductscience.org/library/papers/39043825PubMed
37726283mRNA vaccines in disease prevention and treatment.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37726283PubMed
37403095Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy.J Nanobiotechnology2023https://conductscience.org/library/papers/37403095PubMed
37323948Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis.Int J Nanomedicine2023https://conductscience.org/library/papers/37323948PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35339668

GET https://conductscience.org/api/papers/v1/35339668/authors